全文获取类型
收费全文 | 11629篇 |
免费 | 534篇 |
国内免费 | 79篇 |
专业分类
耳鼻咽喉 | 262篇 |
儿科学 | 523篇 |
妇产科学 | 535篇 |
基础医学 | 953篇 |
口腔科学 | 548篇 |
临床医学 | 1038篇 |
内科学 | 2557篇 |
皮肤病学 | 159篇 |
神经病学 | 631篇 |
特种医学 | 399篇 |
外国民族医学 | 7篇 |
外科学 | 2283篇 |
综合类 | 251篇 |
一般理论 | 2篇 |
预防医学 | 546篇 |
眼科学 | 357篇 |
药学 | 685篇 |
中国医学 | 46篇 |
肿瘤学 | 460篇 |
出版年
2023年 | 105篇 |
2022年 | 203篇 |
2021年 | 320篇 |
2020年 | 228篇 |
2019年 | 304篇 |
2018年 | 351篇 |
2017年 | 267篇 |
2016年 | 312篇 |
2015年 | 362篇 |
2014年 | 441篇 |
2013年 | 598篇 |
2012年 | 836篇 |
2011年 | 785篇 |
2010年 | 485篇 |
2009年 | 431篇 |
2008年 | 762篇 |
2007年 | 842篇 |
2006年 | 834篇 |
2005年 | 764篇 |
2004年 | 595篇 |
2003年 | 532篇 |
2002年 | 419篇 |
2001年 | 205篇 |
2000年 | 186篇 |
1999年 | 173篇 |
1998年 | 72篇 |
1997年 | 56篇 |
1996年 | 52篇 |
1995年 | 33篇 |
1994年 | 32篇 |
1993年 | 30篇 |
1992年 | 48篇 |
1991年 | 60篇 |
1990年 | 54篇 |
1989年 | 39篇 |
1988年 | 42篇 |
1987年 | 48篇 |
1986年 | 31篇 |
1985年 | 23篇 |
1984年 | 21篇 |
1983年 | 22篇 |
1980年 | 13篇 |
1979年 | 13篇 |
1978年 | 14篇 |
1977年 | 19篇 |
1974年 | 15篇 |
1973年 | 19篇 |
1972年 | 17篇 |
1970年 | 19篇 |
1969年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 12 毫秒
991.
Erdogan M Solmaz S Canataroglu A Kulaksızoglu M Cetinkalp S Ozgen AG Saygili F Yilmaz C 《Endocrine》2010,37(3):449-454
Plasma TAFI may participate in arterial thrombosis in cardiovascular diseases (CVD) and may be involved in the mechanism of vascular endothelial damage in diabetic patients. The aim of this study was to investigate the association of plasma TAFI antigen level in the development of diabetic foot ulcer in Type 2 diabetes. The TAFI antigen levels were determined in 50 patients with diabetic foot ulcers and 34 patients without diabetic foot ulcers and 25 healthy individuals. We measured TAFIa/ai antigen in plasma samples with a commercially available ELISA Kit. Diabetic foot ulcer group and diabetic group were similar in terms of mean age and sex distribution. Diabetes duration, retinopathy, neuropathy, macrovascular disease and infection were related to diabetic foot ulcers. HbA1c, HDL-cholesterol and Folic Acid levels were decreased in the diabetic foot ulcer group. TAFI levels were 99.44?±?55.94% in control group, 135.21?±?61.05% in diabetic foot ulcer group, 136.75?±?59.38% in diabetic group and was statistically different (P?0.05). But no difference was seen in TAFI levels between the diabetic foot ulcer group and diabetic group (P?>?0.05). No significant difference in plasma TAFI levels were seen between diabetic foot ulcer stages. TAFI antigen levels are increased in Type 2 diabetic patients, but are not related to diabetic foot ulcer development. 相似文献
992.
993.
Muhammet Cinar Ayhan Dinc Ismail Simsek Hakan Erdem Bayram Koc Salih Pay Selim Kilic 《Rheumatology international》2010,30(8):1141-1141
994.
995.
Faouzi Addad Tahar Chakroun Ismail Elalamy Fatma Abderazek Saoussen Chouchene Zohra Dridi Gregoris T. Gerotziafas Mohamed Hatmi Mohsen Hassine Habib Gamra 《International journal of hematology》2010,92(2):296-301
The aim of this pilot study was to compare the effect of two different regimens of aspirin dosage on platelet of coronary
artery disease (CAD) diabetic patients. Twenty-five CAD diabetic patients were included. Initially, all patients received
aspirin 100 mg/day for 10 days. At day 10, aspirin antiplatelet effect was determined by measuring the collagen/epinephrine
closure time (CT) 2 h after the last aspirin dosage and the next morning at 8 a.m.. The aspirin regimen was modified to 100 mg
twice daily for patients showing a non-optimal platelet-inhibitory effect (CT < 298 s at 8 a.m.). Persistent high platelet
reactivity (HPR) was defined by a CT < 160 s. During the 100 mg/day aspirin regimen, the prevalence of HPR at 8 a.m. was 48%,
and only 7 patients (28%) had showed an optimal platelet-inhibitory effect. Bridging to the twice-daily regimen, the HPR was
significantly reduced (p = 0.025), and the optimal platelet-inhibitory effect was reached for 3 other patients. Our results showed that 100 mg aspirin
twice-daily dosing rather than a once-daily dose significantly improves the aspirin effect on platelet of CAD diabetic patients.
However, large prospective studies were needed to confirm whether this strategy will be clinically relevant and safe. 相似文献
996.
Michael Walsh Aylin Sar Diane Lee Serdar Yilmaz Hallgrimur Benediktsson Braden Manns Brenda Hemmelgarn 《Clinical journal of the American Society of Nephrology》2010,5(3):425-430
Background and objectives: IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. Accurately identifying patients who are at risk for progressive disease is challenging. The extent to which histopathologic features improves prognostication is uncertain.Design, setting, participants, & measurements: We studied a retrospective cohort with biopsy-proven IgAN in Calgary, Canada. Renal biopsies were reviewed by a nephropathologist with histopathologic data abstracted using a standardized form. The primary outcome was the composite of doubling of serum creatinine, ESRD, or death. Spline models defined significant levels of interstitial fibrosis, glomerulosclerosis, hypertension, proteinuria, and creatinine. The prognostic significances of clinical and histopathologic parameters were determined using Cox proportional hazards models.Results: Data from 146 cases were available for analysis with a median follow-up of 5.8 years. Greater than 25% interstitial fibrosis, >40% glomerular sclerosis, and a systolic BP >150 mmHg were risk thresholds. In univariable analyses, baseline creatinine, proteinuria, systolic BP, glomerular sclerosis, interstitial fibrosis, and crescentic disease were predictors of the primary outcome. In multivariable models adjusted for clinical characteristics, interstitial fibrosis (hazard ratio [HR]2.7; 95% confidence interval [CI] 1.2 to 6.0), glomerular sclerosis (HR 2.6; 95% CI 1.2 to 4.5), and crescents (HR 2.4; 95% CI 1.2 to 5.1) remained independent predictors of the primary outcome and significantly improved model fit compared with clinical characteristics alone.Conclusions: Baseline histopathologic parameters are independent predictors of adverse outcomes in IgAN even after taking into consideration clinical characteristics. Relatively small degrees of interstitial fibrosis confer an increased risk for progressive IgAN.IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Patients with IgAN have a variable clinical course with between 6 and 43% progressing to ESRD over 10 yr (1–5). Given this variability, identifying reliable prognostic factors is important to help stratify clinical monitoring and treatment regimens.Previous studies have identified clinical features including high-grade proteinuria, reduced kidney function, and hypertension at the time of diagnosis as predictors of adverse outcomes (4–7). Studies have identified interstitial fibrosis and glomerular sclerosis as poor prognostic features (8–10). This is not surprising considering that these features are a common final result of damage from glomerulonephritis; however, histopathologic features frequently correlate with serum creatinine, and whether they add prognostic values beyond the measurement of serum creatinine is uncertain. Histopathologic features are commonly categorized on the basis of arbitrary thresholds to denote significant degrees of damage (3,5,11), a factor that may contribute to poor performance in multivariable models of risk prediction in IgAN and result in an underestimation of their ability independently to predict outcomes. We performed a retrospective study using detailed baseline clinical data and quantitative analysis of renal biopsies, including the degree of interstitial fibrosis and glomerulosclerosis, to assess the factors that determine adverse outcomes including chronic kidney disease (CKD) progression and death. 相似文献
997.
Mauricio Monroy-Cuadros Serdar Yilmaz Anastasio Salazar-Ba?uelos Christopher Doig 《Clinical journal of the American Society of Nephrology》2010,5(10):1787-1792
Background and objectives: Clinical guidelines support vascular access surveillance to detect access dysfunction and alter the clinical course by radiologic or surgical intervention. The objective of this study was to explore the association between loss of primary functional patency within 6 months of first use and demographic and clinical characteristics of patients receiving chronic renal replacement therapy with arteriovenous fistulas.Design, setting, participants, & measurements: This was a retrospective study of all chronic hemodialysis patients followed by the Southern Alberta Renal Program from January 1, 2005 to June 30, 2008. Demographic and clinical variables and initial intra-access blood flow (IABF) were compared between those with and without loss of primary functional patency. To determine the contribution of independent variables to the dependant variable of loss of primary functional patency, a multivariable analysis using logistic regression was performed.Results: The incidence of primary failure was 10% (81 of 831). Multivariable analysis found that older age (>65 years, odds ratio [OR] 3.6, P < 0.001), history of diabetes (OR 2.3, P = 0.007), history of smoking (OR 4.3, P < 0.001), presence of forearm fistulas (OR 4.0, P < 0.001), and low initial IABF (<500 ml/min, OR 29, P < 0.001) were independently associated with loss of primary patency.Conclusions: The set of patient risk factors identified in this study, particularly initial IABF, can be used to identify patients who are most at risk for developing vascular access failure and to guide a more directed approach for a vascular access screening protocol.A significant challenge for physicians and other healthcare professionals who care for patients with chronic renal failure is the preservation of vascular access for hemodialysis. Vascular access failure, particularly loss of primary functional patency of a surgically created access, is a cause of considerable morbidity, discomfort, inconvenience, and cost. Approximately 20% to 30% of all hospital admissions for patients with ESRD are related to complications of vascular access (1–4). To decrease the incidence of loss of primary functional patency, the National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines recommend that all vascular accesses undergo regular surveillance by measurement of the intra-access blood flow (IABF) to identify hemodynamically significant dysfunction (5). Although following these guidelines leads to the identification of access dysfunction in arteriovenous fistulas (AVFs) and grafts, there remains considerable room for improvement. For example, identification of major risk factors for problems with access patency might allow redirection of surveillance effort away from patients with few risk factors toward those with more risk factors. The main objective of this study was to explore the association between loss of primary functional patency within 6 months of first use and demographic and clinical characteristics in patients with AVFs receiving chronic renal replacement therapy. 相似文献
998.
999.
With the continuing epidemics of obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) has received increased attention. Great efforts are being undertaken to improve the noninvasive diagnosis of NAFLD, with the ultimate goal of optimizing treatment options and clinical outcomes. Research suggests that blood-borne biochemical markers can be used to distinguish simple steatosis from nonalcoholic steatohepatitis (NASH), thus reducing the need of liver biopsy. Future developments in the field of diagnostic biochemistry within the spectrum of NAFLD can make this approach ideal for screening and monitoring purposes. In this review, we provide an overview of the different blood-borne markers which have been recently proposed for differentiating simple steatosis from NASH. We will also consider the practical and statistical issues that seem to be limiting the effective integration of biomarkers into clinical development. 相似文献
1000.